Axsome Therapeutics AXSM Cash Flow Statement
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| -$188.3M-2.8% | -$183.17M+20.2% | -$229.53M+7.0% | -$246.9M+11.3% | -$278.27M+3.1% | ||
| $470K-6.6% | $503K-2.9% | $518K-2.1% | $529K-3.6% | $549K+3.2% | ||
| $93.88M+0.1% | $93.75M+0.8% | $93.01M+1.6% | $91.57M+3.7% | $88.34M+3.7% | ||
| $91.98M+8.5% | $84.78M+13.5% | $74.73M-4.8% | $78.48M+30.9% | $59.96M+27.1% | ||
| $13.52M+26.8% | $10.66M— | —— | —— | —— | ||
| —— | —— | -$10.03M-133% | $30.29M-5.0% | $31.87M+1.8% | ||
| $100.15M+19.6% | $83.74M-18.1% | $102.24M+91.8% | $53.32M-18.4% | $65.3M+16.5% | ||
| $6.38M0.0% | $6.38M0.0% | $6.38M0.0% | $6.37M0.0% | $6.38M-0.3% | ||
| —— | —— | —— | —— | -$108.5K+74.3% | ||
| $795K-39.0% | $1.3M-29.6% | $1.85M-21.7% | $2.36M-12.1% | $2.69M+1.8% | ||
| -$71.78M+24.0% | -$94.45M+7.4% | -$102M+15.4% | -$120.63M-2.0% | -$118.32M+7.9% | ||
| $263K-45.2% | $480K+9.3% | $439K-6.8% | $471K-7.6% | $510K+88.9% | ||
| -$263K+45.2% | -$480K-9.3% | -$439K+6.8% | -$471K+7.6% | -$510K-88.9% | ||
| —— | —— | —— | —— | —— | ||
| $54.6M-19.6% | $67.9M-13.7% | $78.65M-3.9% | $81.8M+41.2% | $57.93M+42.0% | ||
| $2.4M+12.8% | $2.12M+11.0% | $1.91M+22.6% | $1.56M+27.0% | $1.23M+24.0% | ||
| $12.08M+69.8% | $7.11M+7.7% | $6.6M+5.9% | $6.23M-6.6% | $6.67M+68.8% | ||
| $75.19M-25.9% | $101.47M+2.2% | $99.32M-8.4% | $108.46M+22.8% | $88.3M+52.7% | ||
| —— | —— | —— | —— | —— | ||
| $12.97M-11.3% | $14.63M-10.4% | $16.33M-10.0% | $18.14M-6.4% | $19.38M-1.6% | ||
| $795K-39.0% | $1.3M-29.6% | $1.85M-21.7% | $2.36M-12.1% | $2.69M+1.8% | ||
| $6.38M0.0% | $6.38M0.0% | $6.38M0.0% | $6.37M0.0% | $6.38M-0.3% | ||
| -$3.4M-37.3% | -$2.47M-114% | $17.58M-15.4% | $20.79M-33.1% | $31.05M+10.4% | ||
| $470K-6.6% | $503K-2.9% | $518K-2.1% | $529K-3.6% | $549K+3.2% | ||
| —— | —— | —— | —— | —— | ||
| —— | —— | —— | —— | -$108.5K+74.3% | ||
| $100.15M+19.6% | $83.74M-18.1% | $102.24M+91.8% | $53.32M-18.4% | $65.3M+16.5% | ||
| —— | —— | —— | —— | —— | ||
| $3.28M+7.7% | $3.05M+17.4% | $2.6M+22.5% | $2.12M+29.4% | $1.64M+17.9% | ||
| $5.97M+15.6% | $5.16M-36.9% | $8.17M— | —— | —— | ||
| $2.4M+12.8% | $2.12M+11.0% | $1.91M+22.6% | $1.56M+27.0% | $1.23M+24.0% | ||
| -$10.92M-9.8% | -$9.94M-8.9% | -$9.13M-6.6% | -$8.56M-3.8% | -$8.24M-4.8% | ||
| $899K-24.9% | $1.2M-16.2% | $1.43M-4.9% | $1.5M+24.2% | $1.21M+48.2% | ||
| $52.5M-11.8% | $59.56M+31.3% | $45.37M-9.5% | $50.13M— | —— | ||
| $2.45M+12.2% | $2.19M+11.0% | $1.97M+22.4% | $1.61M+20.5% | $1.34M+29.2% | ||
| —— | —— | —— | —— | —— | ||
| $6.41M+42.2% | $4.51M-7.2% | $4.86M+54.6% | $3.14M-28.5% | $4.4M-17.9% | ||
| —— | —— | —— | —— | —— | ||
| —— | —— | —— | —— | —— | ||
| -$71.98M+24.1% | -$94.87M+7.3% | -$102.38M+15.5% | -$121.1M-1.9% | -$118.83M+7.7% | ||
| -$71.98M+24.1% | -$94.87M+7.3% | -$102.38M+15.5% | -$121.1M-1.9% | -$118.83M+7.7% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How much cash does Axsome Therapeutics generate?
- Axsome Therapeutics (AXSM) generated -$71.8M in operating cash flow over the trailing twelve months.
- What is Axsome Therapeutics's free cash flow?
- After $263.0K of capital expenditures, Axsome Therapeutics's free cash flow was -$72.0M over the trailing twelve months, up 39.4% year over year.
- Where does Axsome Therapeutics's cash flow data come from?
- Every line is extracted from Axsome Therapeutics's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
